LAVA Therapeutics (NASDAQ:LVTX) Receives Market Perform Rating from JMP Securities

JMP Securities reissued their market perform rating on shares of LAVA Therapeutics (NASDAQ:LVTX) in a research report sent to investors on Wednesday morning, Marketbeat reports. JMP Securities currently has a $6.00 price target on the stock.

LAVA Therapeutics Trading Down 7.5 %

Shares of NASDAQ:LVTX opened at $1.11 on Wednesday. LAVA Therapeutics has a 1 year low of $1.08 and a 1 year high of $6.47. The business has a fifty day simple moving average of $1.69 and a 200 day simple moving average of $1.83.

Institutional Investors Weigh In On LAVA Therapeutics

Several institutional investors have recently made changes to their positions in the company. Pathway Financial Advisors LLC increased its holdings in LAVA Therapeutics by 70.8% in the third quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock worth $170,000 after buying an additional 42,500 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of LAVA Therapeutics during the 2nd quarter worth $55,000. Finally, Virtu Financial LLC bought a new position in shares of LAVA Therapeutics during the 3rd quarter valued at $32,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.